Saclarides Theodore J
Rush Medical College, Section of Colon and Rectal Surgery, Rush University Medical Center, Chicago, IL 60612, USA.
J Perianesth Nurs. 2006 Apr;21(2A Suppl):S7-15. doi: 10.1016/j.jopan.2006.01.008.
Postoperative ileus (POI) is frequently experienced by many patients undergoing abdominal operations and other surgical procedures. Postoperative ileus causes physical discomfort and may increase risk for prolonged hospital length of stay. Despite its prevalence, there is currently no accepted standard definition of POI and, consequently, no standardized mode of prevention or treatment; it is no wonder that a variety of management approaches for POI have been developed. Some of these include alternative surgical techniques such as laparoscopic or endoscopic procedures to minimize trauma and help lessen the release of endogenous mediators of POI. Others have evaluated alternate analgesic regimens such as thoracic epidural anesthetics to avoid stimulating opioid receptors in the gut. These approaches have had varying results. Other pharmacologic attempts to reduce POI have focused on the blockade of opioid receptors to prevent opioid-induced GI-related adverse effects. A new class of agents, peripherally acting mu-opioid-receptor antagonists such as methylnaltrexone and alvimopan, may improve the pharmacologic management of POI and reshape the current paradigm of multimodal management of POI. Protocols that incorporate these agents may offer yet another avenue to mitigate the adverse effects of POI, and thus help improve surgical outcomes. To date, alvimopan has been shown in phase 3 clinical trials to significantly reduce the duration of POI while maintaining satisfactory analgesia and reducing length of hospital stay. Combinations of strategies with demonstrated effectiveness such as early feeding, epidural analgesia, laparoscopic surgery, and peripherally acting mu-opioid-receptor antagonists may help transform the management of POI into an effective multimodal paradigm that targets the diverse etiologic factors leading to this common clinical problem. Clearly, all surgical team members are crucial in the optimal implementation of such multimodal approaches.
许多接受腹部手术及其他外科手术的患者经常会出现术后肠梗阻(POI)。术后肠梗阻会引起身体不适,并可能增加延长住院时间的风险。尽管其很常见,但目前尚无公认的POI标准定义,因此也没有标准化的预防或治疗模式;难怪已经开发出了多种POI管理方法。其中一些方法包括替代手术技术,如腹腔镜或内镜手术,以尽量减少创伤并有助于减少POI内源性介质的释放。其他方法则评估了替代镇痛方案,如胸段硬膜外麻醉,以避免刺激肠道中的阿片受体。这些方法取得了不同的结果。其他减少POI的药物尝试集中在阻断阿片受体以预防阿片类药物引起的胃肠道相关不良反应。一类新型药物,如甲基纳曲酮和阿维莫潘等外周作用的μ-阿片受体拮抗剂,可能会改善POI的药物管理,并重塑当前POI多模式管理的范式。纳入这些药物的方案可能会提供另一种减轻POI不良反应的途径,从而有助于改善手术结果。迄今为止,阿维莫潘已在3期临床试验中显示出可显著缩短POI持续时间,同时保持满意的镇痛效果并缩短住院时间。将早期进食、硬膜外镇痛、腹腔镜手术和外周作用的μ-阿片受体拮抗剂等已证明有效的策略相结合,可能有助于将POI的管理转变为一种有效的多模式范式,该范式针对导致这一常见临床问题的多种病因。显然,所有手术团队成员对于最佳实施此类多模式方法都至关重要。